Trametinib Dimethyl Sulfoxide

Preferred Label : Trametinib Dimethyl Sulfoxide;

NCIt definition : A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.;

UNII : BSB9VJ5TUT;

InChIKey : OQUFJVRYDFIQBW-UHFFFAOYSA-N;

CAS number : 1187431-43-1;

Drug name : Mekinist; Meqsel; Spexotras;

NCI Metathesaurus CUI : CL553915;

Details

Origin ID

C152711;

UMLS CUI

C3644500;

Currated CISMeF NLP mapping
- Trametinib dimethyl sulfoxide [SMS substance]
- Trametinib dimethyl sulfoxide (substance) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Trametinib dimethyl sulfoxide (substance) [SNOMED CT concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 [NCIt concept]
- Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 [NCIt concept]
is_component_of_chemotherapy_regimen
- Dabrafenib/Pembrolizumab/Trametinib Regimen [NCIt concept]
- Trametinib Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients